MCG as a Noninvasive Diagnostic Strategy for Suspected INOCA (MICRO2) (MICRO2)
Magnetocardiography as a Noninvasive Diagnostic Strategy for Suspected Myocardial Ischemia With No Obstructive Coronary Artery Disease
Sponsor: Genetesis Inc.
This observational or N/A phase trial investigates Angina and Coronary Microvascular Disease and is currently completed. Genetesis Inc. leads this study, which shows 9 recorded versions since 2024 — indicating limited longitudinal coverage. Heart and vascular conditions benefit from the kind of long-term tracking this trial provides.
Status Flow
Change History
9 versions recorded-
Aug 2025 — Present [monthly]
Completed
Status: Recruiting → Completed
-
Jun 2025 — Aug 2025 [monthly]
Recruiting
-
Mar 2025 — Jun 2025 [monthly]
Recruiting
-
Nov 2024 — Mar 2025 [monthly]
Recruiting
-
Sep 2024 — Nov 2024 [monthly]
Recruiting
▶ Show 4 earlier versions
-
Aug 2024 — Sep 2024 [monthly]
Recruiting
Status: Not Yet Recruiting → Recruiting
-
Jul 2024 — Aug 2024 [monthly]
Not Yet Recruiting
-
Jun 2024 — Jul 2024 [monthly]
Not Yet Recruiting
-
Feb 2024 — Jun 2024 [monthly]
Not Yet Recruiting
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Genetesis Inc.
For direct contact, visit the study record on ClinicalTrials.gov .